Panbela Therapeutics Q2 EPS $(7.95) Misses $(4.70) Estimate
Portfolio Pulse from mahesh@benzinga.com
Panbela Therapeutics reported Q2 losses of $7.95 per share, missing the analyst consensus estimate of $4.70 by 69.15%. This represents a 99.56% increase over losses from the same period last year.
August 10, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Panbela Therapeutics' Q2 earnings were significantly below analyst estimates, with losses per share increasing by 99.56% compared to the same period last year.
Panbela Therapeutics reported a significant miss on its Q2 earnings, with losses per share far exceeding analyst estimates. This is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100